Compared to symptomatic therapy, patient with AR treated with allergen immunotherapy obtained approx. 0.75 month (3 years of vaccination followed by 5-year evaluation) and 3.45 month (4-year follow up including 3 years of vaccination) without AB. The QALY for costs has been calculated between 8516 €-8883 €. CONCLUSIONS: In the Slovak Republic, Staloral allergen immunotherapy of allergic rhinitis is effective from the clinical as well as pharmacoeconomic point of view.

No abstract

A349 transformed to common logarithms. Costs are stated in € (1€ = 25.5CZK). Results: A total 100 patients (about 10-15% of all HIV treated in the Czech Republic) were included. The mean age was 41.9 years (range 23-71), time since diagnosis 5.8 years (range 1-26), and period of assessment 30.5 months. Average total annual costs were highest for CD4+ <200 (22,905€ ; p<0.05) vs. CD4+ 200-499 (17,801€) and CD4+ >500 (17,043€). HIV medication accounted for the majority of costs in all three subgroups (range 62% in CD4+ <200 to 88% in CD4+ >500). Patients with a disease duration of >10 years had highest annual costs of 22,841€ (p<0.05) compared to 15,783€ (duration 5-10 years) and 16,777€ (<5 years). HIV-medication accounted for the majority of costs here as well (from 70% to 88%; NS). In this analysis 17 % of costs in patients with disease duration of >10 years were due to hospitalization vs. 5 % in both other groups (NS). ConClusions: Similarly to published literature, we found highest costs in patients with low CD4+ lymphocytes and longer disease duration.